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English	  Abstract	  	  This	  paper	  is	  the	  result	  of	  a	  collaborative	  work	  between	  researchers	  based	  in	  UK,	  Italy,	  China	  and	  Brazil,	   and	  aims	  at	  providing	  a	   comprehensive	   review	  of	  practices	  and	  meanings	  of	  Non-­‐Invasive	  Prenatal	   Testing	   (NIPT)	   in	   these	   countries,	   while	   also	   highlighting	   the	   ethical	   implications	   that	  NIPT	  poses.	  In	  the	  first	  part	  of	  this	  paper	  we	  describe	  how	  the	  technology	  is	  being	  integrated	  into	  the	   ‘moral	   economy’	   of	   prenatal	   testing	   in	   the	  different	   countries	  we	   analysed.	  The	  uses	   of	  NIPT	  differ	  greatly	  in	  the	  countries	  we	  analysed.	  	  In	  the	  second	  section	  of	  the	  paper	  we	  position	  NIPT	  within	  the	  trajectory	  of	  prenatal	  diagnosis	  that,	  displays	   the	   role	   of	   conflicting	   values	   and	   often	   incommensurable	   moral	   economies	   in	   the	  emergence	  of	  new	  technologies,	  and	  in	  their	  transformation	  into	  routine	  medical	  procedures.	  	  The	  two	   ‘often	   incommensurable	   moral	   economies’	   are	   women’s	   autonomy	   and	   individual-­‐centred	  medicine,	   as	   emphasised	   in	   gynaecologists	   and	   midwives/obstetricians’	   public	   discourse;	   and	  considerations	  about	  the	  cost/efficacy	  of	  long-­‐term	  care	  for	  people	  with	  Down	  Syndrome	  or	  other	  chromosomal-­‐related	  disabilities	  as	  emphasized	  in	  public	  health	  discourses.	  We	  discuss	  how	  these	  two	  contrasting	  narratives	  are	  also	  at	  play	  (more	  or	   less	  covertly)	   in	  the	  discourses	  around	  NIPT.	  We	  then	  consider	  some	  of	  the	  ethical	  issues	  raised	  by	  NIPT,	  including	  the	  argument	  that	  NIPT	  will	  lead	   to	   a	   harmful	   bias	   towards	   people	   with	   Down	   Syndrome	   and	   to	   an	   increase	   in	   termination	  rates;	   and	   the	   ethical	   issues	   raised	   possible	   incidental	   findings	   resulting	   from	   a	   maternal	  chromosomal	  mosaicisms	  due	  to	  an	  anomalous	  cellular	  line,	  and	  other	  hidden	  abnormalities	  in	  one	  of	  the	  parents,	  including	  genetic	  diseases	  with	  late	  expressions	  in	  life.	  We	  note	  how	  the	  counselling	  step	   following	   incidental	   finding	   will	   be	   of	   the	   utmost	   importance	   and	   that	   in	   many	   countries,	  including	  the	  ones	  we	  analysed,	  doctors	  and	  healthcare	  professionals	  are	  not	  adequately	  prepared	  for	   it.	   We	   conclude	   that	   it	   is	   important	   that	   bioethics	   scholarship	   engages	   proactively	   with	   the	  ethical	  issues	  that	  arise	  at	  the	  nexus	  of	  these	  conflicting	  values	  and	  moral	  economies,	  especially	  as	  future	   evolutions	   of	   NIPT	   combined	   with	   whole	   genome	   sequencing	   (WGS)	   will	   affect	   women’s	  reproductive	  decisions,	  and	  shape	  the	  scope	  of	  their	  reproductive	  choices,	  in	  a	  way	  that	  will	  lead	  to	  a	   completely	   new	   level	   of	   ‘supervision’,	   ‘management’	   and	   ‘scrutiny’	   of	   human	   foetuses	   and	  pregnant	  women.	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French	  Abstract	  	  Cet	  article	  est	  le	  résultat	  d'une	  collaboration	  entre	  des	  chercheurs	  qui	  ont	  étudié	  l'évolution	  du	  diagnostique	  prénatal	  au	  Royaume	  Uni,	  en	  Italie,	  en	  Chine	  et	  au	  Brésil.	  Il	  passe	  en	  revue	  les	  pratiques	  liées	  à	  l'introduction	  des	  tests	  prénataux	  non	  invasifs	  (NIPT)	  dans	  ces	  pays,	  et	  discute	  les	  questions	  éthiques	  liées	  à	  l'introduction	  de	  cette	  nouvelle	  approche	  diagnostique.	  En	  	  Chine,	  en	  Italie,	  au	  Royaume	  Uni	  et	  au	  Brésil	  le	  NIPT	  est	  déjà	  présent	  sur	  le	  marché.	  Toutefois,	  bien	  que	  la	  technologie	  utilisée	  pour	  analyser	  l'ADN	  fœtal	  dans	  la	  circulation	  maternelle	  soit	  bien	  établie	  et	  semblable	  partout,	  et	  que	  tous	  les	  producteurs	  commerciaux	  de	  NIPT	  proposent	  des	  services	  équivalents,	  les	  trajectoires	  situés	  de	  cette	  nouvelle	  approche	  diagnostique	  ont	  été	  très	  différents.	  Ceci	  n'est	  nullement	  étonnant.	  Les	  applications	  d'une	  technologie	  biomédicale	  sont	  toujours	  situés,	  et	  dépendent	  du	  contexte	  social,	  culturel,	  économique	  et	  politique	  dans	  lequel	  elle	  est	  introduite.	  La	  première	  partie	  de	  ce	  texte	  décrit	  l'intégration	  du	  NIPT	  dans	  les	  structures	  préexistantes	  du	  diagnostique	  prénatal	  dans	  chacun	  des	  pays	  étudiés.	  Le	  18	  Janvier	  2016	  le	  comité	  national	  chargé	  des	  tests	  de	  dépistage	  au	  Royaume	  Uni	  (UK	  National	  Screening	  Committee)	  a	  constaté	  	  que	  le	  NIPT	  prédit	  avec	  précision	  la	  présence	  du	  syndrome	  de	  Down	  (trisomie	  21),	  du	  syndrome	  d'Edwards	  (trisomie	  18)	  et	  du	  syndrome	  de	  Patau	  (trisomie	  13),	  et	  a	  recommandé	  que	  le	  NHS	  (National	  Health	  Service)	  diffuse	  le	  NIPT	  pour	  ces	  trois	  conditions.	  De	  toute	  vraisemblance,	  en	  2017	  ou	  2018	  ce	  test	  sera	  proposé	  à	  toutes	  les	  femmes	  enceintes	  au	  Royaume	  Uni,	  indépendamment	  de	  leur	  risque	  d'avoir	  un	  enfant	  trisomique.	  Les	  medias	  et	  certains	  experts	  ont	  argumenté	  que	  la	  mise	  en	  oeuvre	  du	  NIPT	  au	  Royaume	  Uni	  à	  travers	  le	  NHS	  va	  produire	  une	  véritable	  révolution	  du	  diagnostique	  prénatal.	  Nous	  	  proposons,	  par	  contre,	  que	  de	  toute	  vraisemblance	  cette	  démarche	  va	  conduire	  à	  une	  'modulation'	  plutôt	  qu'à	  une	  'révolution',	  des	  pratiques	  du	  diagnostique	  prénatal.	  En	  Italie	  plusieurs	  groupes	  régionales	  et	  nationales	  sont	  en	  train	  d'évaluer	  la	  possibilité	  d'introduire	  le	  NIPT	  dans	  le	  système	  de	  santé	  national.	  En	  Chine,	  en	  décembre	  2015,	  le	  NIPT	  a	  été	  inclus	  dans	  le	  système	  public	  de	  soins	  anténataux	  de	  la	  ville	  de	  Shenzhen	  (une	  ville	  de	  plus	  de	  10	  millions	  d'habitants)	  ,	  la	  première	  ville	  chinoise	  à	  faire	  ce	  choix.	  A	  Shenzhen,	  les	  femmes	  enceintes	  payent	  88RMB	  (environs	  115	  euros)	  pour	  le	  NIPT;	  le	  restant	  du	  prix	  de	  ce	  test	  (plus	  que	  la	  moitié)	  est	  couvert	  par	  les	  services	  de	  santé	  de	  Shenzhen.	  En	  Chine,	  le	  NIPT	  détecte	  uniquement	  des	  aneuploïdies;	  la	  détection	  du	  sexe	  du	  fœtus	  est	  strictement	  interdite,	  pour	  empêcher	  un	  avortement	  sélectif	  des	  filles.	  Au	  Brésil	  l'avortement	  pour	  une	  indication	  fœtale	  est	  interdit	  (avec	  la	  seule	  exception	  de	  l’anencéphalie)	  et	  le	  système	  national	  de	  santé	  (SUS,	  Sistema	  Unico	  de	  Saude)	  n'offre	  pas	  de	  diagnostique	  prénatal.	  Toutefois,	  les	  femmes	  des	  classes	  moyennes	  et	  supérieures	  utilisent	  exclusivement	  les	  services	  de	  santé	  privés,	  et	  ont	  accès	  aux	  tests	  prénataux	  et	  à	  l'avortement	  (illégal)	  pour	  une	  indication	  fœtale.	  Le	  NIPT	  a	  été	  	  aisément	  intégré	  à	  ce	  système	  privé	  de	  soin.	  Une	  particularité	  du	  système	  brésilien	  est	  une	  diffusion	  large	  des	  tests,	  fondée	  sur	  l'analyse	  de	  l'ADN	  fœtal	  dans	  le	  sang	  de	  la	  mère,	  qui	  détermine	  précocement	  le	  sexe	  du	  fœtus.	  Ces	  tests,	  relativement	  peu	  onéreux,	  ont	  comme	  but	  d'intégrer	  le	  futur	  enfant	  dans	  la	  famille.	  Ils	  ne	  sont	  pas	  liés	  aux	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avortements	  sélectifs,	  puisque	  les	  brésiliens	  n'ont	  pas	  une	  préférence	  forte	  pour	  des	  enfants	  d'un	  sexe	  déterminé.	  La	  deuxième	  partie	  de	  cet	  article	  discute	  les	  problèmes	  éthiques	  soulevés	  par	  l'introduction	  du	  NIPT.	  Notre	  hypothèse	  est	  que	  l'effet	  principal	  de	  la	  généralisation	  du	  NIPT	  sera	  	  probablement	  une	  diminution	  drastique	  du	  nombre	  de	  tests	  invasifs	  :	  l’amniocentèse	  et	  la	  biopsie	  des	  trophoblastes.	  Une	  autre	  conséquence	  potentielle	  sera	  un	  diagnostique	  plus	  précoce	  	  des	  anomalies	  fœtales;	  ceci	  peut	  dans	  certains	  cas	  favoriser	  la	  décision	  de	  terminer	  une	  grossesse.	  	  Nous	  doutons	  néanmoins	  que	  la	  diffusion	  du	  NIPT	  va	  augmenter	  le	  nombre	  d’avortements	  pour	  des	  indications	  fœtales.	  L'introduction	  du	  NIPT	  ne	  va	  probablement	  pas	  changer	  d'une	  manière	  considérable	  le	  taux	  d'interruptions	  de	  grossesses	  pour	  trisomie	  21,	  puisque	  dans	  la	  majorité	  des	  cas	  cette	  condition	  est	  déjà	  détecté	  avant	  la	  naissance	  par	  d’autres	  moyens.	  Le	  NIPT	  ne	  va	  probablement	  pas	  non	  plus	  induire	  une	  hausse	  importante	  d’avortements	  pour	  d'autres	  indications	  fœtales.	  Les	  craintes	  que	  les	  femmes	  allaient	  avorter	  pour	  des	  raisons	  'triviales'	  ou	  pour	  des	  handicaps	  'mineurs",	  fréquemment	  exprimées	  après	  la	  légalisation	  de	  l'avortement	  en	  Europe	  et	  en	  Amérique	  du	  Nord	  dans	  les	  années	  1960	  et	  1970,	  ne	  se	  sont	  jamais	  matérialisées.	  Il	  semble	  donc	  peu	  probable	  que	  le	  NIPT	  va	  favoriser	  l'explosion	  de	  tels	  avortements.	  Toutefois,	  cette	  supposition	  n'est	  pas	  fondée	  sur	  des	  données	  empiriques.	  Il	  sera	  désirable	  d'accompagner	  la	  diffusion	  large	  du	  NIPT	  par	  un	  suivi	  des	  décisions	  de	  femmes	  qui	  ont	  appris	  la	  présence	  d'une	  anomalie	  fœtale	  par	  ce	  test.	  Il	  sera	  aussi	  désirable	  de	  suivre	  les	  conséquences	  de	  la	  révélation	  accidentelle	  des	  problèmes	  maternels/parentaux	  par	  le	  NIPT,	  tel	  le	  mosaïsme	  cellulaire	  chez	  la	  femme	  enceinte,	  ou	  la	  présence	  d'une	  maladie	  génétique	  dans	  la	  famille;	  de	  telles	  révélations	  accidentelles	  	  sont	  un	  des	  problèmes	  éthiques	  les	  plus	  épineux	  liés	  à	  la	  généralisation	  du	  NIPT.	  Les	  femmes	  qui	  reçoivent	  un	  tel	  diagnostique	  accidentel	  ont	  un	  besoin	  urgent	  de	  conseil	  génétique	  de	  qualité,	  mais	  la	  majorité	  des	  médecins	  qui	  prescrivent	  le	  NIPT	  ne	  sont	  pas	  formés	  pour	  le	  fournir.	  En	  outre,	  quand	  le	  NIPT	  est	  distribué	  par	  des	  compagnies	  privées	  et	  pas	  par	  un	  service	  de	  santé	  national,	  il	  y	  a	  un	  risque	  considérable	  que	  ce	  test	  soit	  administré	  dans	  des	  centres	  qui	  ne	  sont	  pas	  équipés	  pour	  assurer	  un	  suivi	  approprié	  des	  femmes	  testés.	  La	  conclusion	  de	  l'article	  discute	  l’intégration	  du	  NIPT	  dans	  un	  ensemble	  de	  tests	  prénataux.	  Ces	  tests	  reflètent	  des	  valeurs	  contradictoires.	  Les	  médecins	  libéraux	  mettent	  en	  avant	  	  la	  nécessité	  de	  respecter	  l'autonomie	  des	  femmes	  et	  des	  couples,	  tandis	  que	  les	  spécialités	  de	  la	  santé	  publique	  avancent	  des	  considérations	  relatives	  au	  cout	  monétaire,	  social	  et	  émotionnel	  des	  soins	  d’individus	  ayant	  des	  problèmes	  graves	  de	  santé.	  Malgré	  l'existence	  d’importantes	  tensions	  et	  contradictions	  autour	  du	  diagnostique	  prénatal,	  les	  technologies	  utilisées	  pour	  surveiller	  le	  développement	  du	  fœtus	  sont	  devenus	  des	  tests	  médicaux	  de	  routine.	  Ceci	  va	  probablement	  être	  également	  le	  devenir	  de	  NIPT.	  Notre	  article	  évoque	  brièvement	  aussi	  des	  futurs	  possibles	  pour	  le	  NIPT,	  avant	  tout	  la	  prédiction	  que	  cette	  technologie	  sera	  bientôt	  couplée	  avec	  le	  séquençage	  complet	  du	  génome	  (Whole	  Genome	  Sqeuencing,	  WGS).	  Un	  tel	  développent	  rendra	  le	  fœtus	  	  encore	  plus	  accessible	  au	  regard	  des	  médecins,	  et	  augmentera	  considérablement	  les	  possibilités	  de	  surveillance	  et	  de	  contrôle	  des	  futurs	  êtres	  humains,	  mais	  aussi	  des	  femmes	  enceintes.	  Il	  est	  donc	  très	  important	  de	  commencer	  dès	  maintenant	  un	  débat	  publique	  sur	  les	  dimension	  éthiques	  d'une	  telle	  évolution,	  et	  d'inclure	  dans	  un	  tel	  débat	  le	  point	  de	  vue	  des	  usagers,	  avant	  tout	  celui	  des	  femmes.	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1. Introduction	  	   This	   is	   a	   fascinating	   time	   to	   discuss	   the	   changing	   landscape	   of	   prenatal	   testing.	   On	  January	   18th,	   2016	   the	   UK	   National	   Screening	   Committee	   reported	   evidence	   that	   Non-­‐Invasive	   Prenatal	   Testing	   (NIPT)	   is	   highly	   accurate	   for	   detection	   of	   foetal	   chromosomal	  aneuploidies	   (the	   presence	   of	   an	   abnormal	   number	   of	   chromosomes)	   including	   the	  detection	   of	   Down	   syndrome	   (trisomy	   21),	   Edwards	   syndrome	   (trisomy	   18)	   and	   Patau	  syndrome	   (trisomy	   13),	   and	   recommended	   it	   for	   implementation	   through	   the	   National	  Health	   Service	   (NHS)	   in	   substitution	   of	   invasive	   screening.	   In	   Italy,	   from	   January	  2016	   a	  private	  company	  (Genoma	  Group)	  is	  the	  first	  to	  offer	  NIPT	  not	  only	  to	  detect	  the	  trisomies	  above	  but	  also	  for	  any	  aneuploidy	  and	  structural	  chromosomal	  alterations	  (deletions	  and	  duplications)	  on	  each	   chromosome.	   In	  Brazil,	   the	  NIPT	  market	  has	   flourished	  among	   the	  upper-­‐middle	  class	  in	  the	  last	  three	  years	  and	  offers	  testing	  mainly	  for	  sex-­‐determination.	  To	   the	   contrary,	   China,	   which	   had	   offered	   NIPT	   since	   2011,	   put	   a	   hold	   to	   all	   testing	   in	  February	  2014	  because	  of	  what	  was	  perceived	  as	  an	  unregulated	  and	  chaotic	  commerical	  market.	   	  Since	  June	  2014	  NIPT	  has	  been	  offered	  again	  for	  aneuploidies	   in	  the	  province	  of	  Shenzen,	  but	  not	  for	  the	  detection	  of	  fœtal	  sex	  which	  remains	  strictly	  prohibited	  	   Commercial	  companies	  in	  many	  countries	  worldwide,	  including	  the	  UK,	  China,	  Italy	  and	   Brazil	   already	   offer	   NIPT.	   In	   the	   first	   years	   since	   its	   introduction,	   NIPT	   has	   been	  promoted	   as	   an	   upscale	   product,	   one	   of	   the	   components	   of	   a	   ‘quality	   pregnancy	   care’	  available	   to	  affluent	  women	  able	   to	  pay	   for	   this	   test	  out	  of	   their	  pocket	   [1].	  This	   is	  what	  currently	  happens	  in	  Italy	  and	  the	  UK,	  and	  in	  some	  parts	  of	  China	  too.	  Such	  a	  use	  of	  NIPT	  in	  a	   ‘middle	   income’	   country	   like	   Brazil	   is	   not	   self-­‐evident.	   In	   such	   countries,	   NIPT	   can	   be	  mobilised	   to	   improve	   women's	   access	   to	   prenatal	   diagnosis,	   especially	   outside	   urban	  centres.	  Blood	  samples	  of	  pregnant	  women	  can	  be	  taken	  by	  community	  health	  workers	  and	  sent	   to	   central	   laboratories,	   reducing	   the	   need	   for	   professionals	   to	   perform	   invasive	  procedures	  and	  interpret	  tests	  results.	  Such	  a	  scenario	  assumes,	  however,	  a	  willingness	  to	  diffuse	   prenatal	   testing	   and,	   implicitly,	   a	   possibility	   to	   abort	   impaired	   foetuses.	   Neither	  exists	  in	  Brazil,	  where	  NIPT	  has	  become	  a	  ‘status	  symbol’	  for	  upper-­‐middle	  class	  that	  uses	  it	  mainly	  for	  sex-­‐determination	  early	  in	  the	  pregnancy,	  as	  described	  below.	  It	   is	   often	   read	   that	   the	  expected	   implementation	  of	  NIPT	   through	   the	  public	  health	  system	   in	   the	   UK	   and	   in	   other	   countries	   including	   Italy	   in	   the	   near	   future	   promises	   to	  ‘revolutionise’	  the	  landscape	  of	  prenatal	  testing.	  But,	  as	  we	  argue	  in	  this	  paper,	  in	  the	  near	  future	   the	   implementation	   of	   NIPT	   through	   the	   national	   health	   system	   will	   lead	   to	   a	  ‘modulation’,	  instead	  than	  a	  ‘revolution’	  of	  the	  landscape	  of	  prenatal	  testing.	  	  This	  paper	  is	  the	  result	  of	  a	  collaborative	  work	  between	  researchers	  based	  in	  UK,	  Italy,	  China	   and	   Brazil,	   and	   aims	   at	   providing	   a	   comprehensive	   review	   of	   practice	   and	   policy	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landscapes	   in	   these	   countries,	   while	   also	   highlighting	   the	   ethical	   implications	   that	   NIPT	  pose.	   As	   the	   technology	   is	   relatively	   simple	   and	   inexpensive,	   but	   with	   manifold	   and	  culturally-­‐	  dependent	  applications,	  it	  is	  important	  to	  discuss	  at	  an	  early	  stage	  how	  NIPT	  is	  changing	   the	   landscape	   of	   prenatal	   testing	   and	   point	   to	   some	   areas	   in	   need	   of	   ethical	  attention.	  	  	  	  	  	  
2.	  	  	  	  	  How	  NIPT	  is	  changing	  the	  landscape	  of	  prenatal	  testing	  
	  	   	  NIPT	  and	  non-­‐invasive	  prenatal	  diagnosis	  (NIPD)	  are	  techniques	  based	  on	  the	  analysis	  of	   maternal	   cell	   free	   foetal	   DNA	   (cffDNA).	   The	   year	   1997	   marked	   a	   milestone	   for	  NIPT/NIPD,	  when	  cffDNA	  was	  found	  in	  maternal	  plasma.	  cffDNA	  originates	  mainly	  from	  the	  placenta,	   and	   is	   constituted	   by	   150-­‐200	   base	   pair	   fragments	   which	   are	   released	   in	   the	  mother’s	   blood,	  where	   it	   is	   first	   detectable	   at	   about	   4-­‐5	  weeks	   of	   gestation.	   At	   about	   10	  weeks,	   the	   concentration	  of	   cffDNA	   reaches	   the	   sufficient	   level	   for	  NIPT	   [2].	   The	   reports	  released	   in	   2008	   by	   two	   independent	   research	   groups	   of	   the	   successful	   non-­‐invasive	  diagnosis	  of	  foetal	  aneuploidy	  by	  using	  massively	  parallel	  genomics	  sequencing	  of	  cffDNA	  in	   maternal	   plasma	   [3,4]	   marked	   the	   real	   breakthrough	   of	   NIPT.	   In	   these	   two	   studies,	  statistics	   was	   used	   to	   diagnose	   the	   foetal	   aneuploidy.	   Both	   teams	   found	   out	   that	   the	  percentage	   of	   cffDNA	   in	   the	   maternal	   plasma	   averages	   around	   10%.	   Assuming	   that	   the	  concentration	  of	  cffDNA	   is	  10%	  of	  maternal	  plasma,	  a	  given	  range	  of	  plasma	  contains	  90	  units	  from	  mother,	  10	  units	  from	  the	  foetus.	  While	  normally	  in	  pregnancy	  the	  total	  quantity	  of	  chromosome	  21	  should	  be	  200	  units	  (mother’s	  chromosome	  21	  is	  90	  units	  *	  2,	  and	  the	  foetus’	  is	  10	  units	  *2),	  in	  case	  of	  trisomy	  21	  (Down	  syndrome)	  210	  units	  are	  counted	  of	  the	  total	   quantity	   of	   chromosome	   21,	   as	   there	   are	   10	   additional	   units	   from	   the	   foetus.	   	   The	  detection	   of	   foetal	   aneuploidies	   (chromosomal	   abnormalities	   in	   terms	   of	   numbers,	   or	  structural	   rearrangements)	   is	   usually	   performed	   through	   invasive	   cytogenetic	   tests	  through	  chorionic	  villus	  sampling	  (CVS)	  at	  weeks	  13+	  6	  weeks,	  or	  amniocentesis	  from	  15+0	  weeks.	  NIPT	   is	  defined	  as	   ‘non-­‐invasive’	  exactly	   in	  contrast	   to	   	  CVS	  or	  amniocentesis,	  which	  pose	  a	  risk	  of	  miscarriage	  of	  about	  0.5-­‐1%	  [5].	  NIPT	  is	  not	  a	  diagnostic	  test,	  as	  it	  requires	  invasive	  test	  confirmation	  through	  either	  CVS	  or	  amniocentesis	  to	  confirm	  the	  diagnosis	  of	  a	   chromosomal	   aneuploidy.	  However,	   as	   explained	   in	  more	  detail	   below,	   the	   accuracy	  of	  the	   test	   has	   been	   constantly	   improving,	   and	   is	   now	   very	   similar	   to	   the	   accuracy	   of	   the	  invasive	  tests.	  As	  such,	   it	   is	  not	   implausible	   to	  speculate	   that	   in	   the	   future	  NIPD	  could	  be	  elevated	  to	  a	  diagnostic	  test,	  and	  will	  nearly	  completely	  substitute	  invasive	  testing,	  at	  least	  for	  some	  applications	  (there	  is	  a	  false	  positive	  rate	  which	  would	  still	  require	  confirmation	  through	  invasive	  screening).	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  In	  Italy,	  where	  one	  of	  the	  authors	  (Zannoni)	   is	  gynaecologist	  working	  in	  a	  university	  research	  hospital	  in	  the	  Emilia-­‐Romagna	  region	  in	  northern	  Italy,	  NIPT	  is	  offered	  by	  private	  companies	   for	   a	   median	   price	   of	   €	   571.	   Regional	   working	   groups	   are	   being	   formed	   to	  evaluate	  NIPT	  and	  then	  formulate	  recommendations	  on	  the	  use	  of	  NIPT	  within	  the	  current	  prenatal	  testing	  system	  for	  the	  diagnosis	  of	  foetal	  chromosomal	  aneuploidies	  (trisomies	  13,	  18,	  and	  31)	  and	  aneuploidies	  of	  sexual	  chromosomes.	  Currently	   all	  women	   in	   Italy	   are	   offered	   a	   combined	   test	   through	   the	   SSN	   (Sistema	  Sanitario	  Nazionale,	   equivalent	   of	   the	  NHS)	   to	   determine	   the	   risk	   of	   foetal	   aneuploidies.	  The	  combined	  test	  determines	  the	  risk	  of	  foetal	  aneuploidies	  through	  an	  algorithm	  [6]	  that	  combines:	   a)	   the	   maternal	   age,	   b)	   the	   values	   of	   two	   serum	   markers	   (maternal	   serum	  pregnancy-­‐associated	   plasma	   protein	   A,	   PAPP-­‐A,	   and	   maternal	   serum	   Beta	   human	  chorionic	   gonadotrophin,	   beta-­‐hCG)	   measured	   between	   10+0	   and	   14+1	   weeks	   of	  gestations,	  and	  c)	  the	  value	  of	  nuchal	  translucency	  measured	  with	  a	  scan	  at	  11+2	  and	  14+0	  weeks	  of	  gestation.	  The	  combined	  test	  offers	  an	  estimate	  of	  the	  individual	  probabilities	  of	  carrying	  a	  foetus	  affected	  by	  trisomy	  13,	  18	  or	  21.	  In	  addition	  the	  combined	  test	  can	  offer	  some	  indications	  to	  determine	  other	  congenital	  anomalies,	  such	  as	  cardiac	  malformations	  [6].	  The	  estimate	  of	  each	  individual	  probability	  is	  compared	  with	  a	  pre-­‐established	  cut-­‐off	  (usually	  1/250	  in	  Italy,	  but	  much	  lower	  in	  UK	  and	  China,	  about	  1/150):	  if	  the	  probability	  is	  below	  1/250,	   the	   result	   of	   the	   combined	   test	   is	   considered	  negative;	   if	   the	  probability	   is	  above	   1/250,	   the	   result	   of	   the	   test	   is	   considered	   positive,	   in	   which	   case	   the	   woman	   is	  offered	   the	  possibility	   to	  undergo	   an	   invasive	   cytogenetic	   test	   (CVS	  or	   amniocentesis)	   to	  confirm	  the	  result	  of	  the	  test.	  Compared	   to	   the	   combined	   test,	   NIPT	   testing	   has	   at	   least	   two	   advantages	   as	   it	  becomes	  better	  able	  to	  provide	  a	  more	  accurate	  estimate	  of	  the	  risk	  of	  trisomies	  13,	  18,	  and	  21.	  There	   is	   increasing	  evidence	   that	  a	  higher	  accuracy	  detection	   rate	  has	  been	  achieved	  with	  NIPT	  compared	  to	  the	  current	  DSS	  [7-­‐10]:	  99.2%	  for	  T21,	  96.3%	  for	  T18	  and	  91%	  for	  T13.	  This	  in	  turn	  leads	  to	  a	  reduction	  in	  the	  number	  of	  false	  positives,	  and	  of	  the	  number	  of	  invasive	   tests	   that	   need	   to	   be	   carried	   out,	   with	   subsequent	   reduction	   in	   the	   risk	   of	  miscarriage	  which	  is	  inherent	  in	  the	  invasive	  tests,	  and	  a	  reduction	  of	  costs	  on	  the	  national	  health	  system	  [1].	  The	  second	  advantage	   is	   that	  NIPT	  offers	  a	  calculation	  of	  risk	  of	   foetal	  aneuploidies	  at	  an	  earlier	  stage	   in	  pregnancy.	  The	  assumption	  here	   is	   that	  earlier	   testing	  potentially	   reduces	   stress	   for	   the	   woman	   in	   the	   case	   of	   a	   positive	   test.	   Since	   early	   in	   a	  pregnancy	  	  the	  woman	  would	  be	  less	  emotionally	  attached	  to	  the	  foetus,	  then	  if	  the	  woman	  decides	   not	   to	   continue	   the	   pregnancy	   an	   abortion	   would	   be	   less	   emotionally	   stressful	  (with	  the	  noted	  exceptions	  of	  course	  of	  a	  pregnancy	  considered	  to	  be	  ‘precious’	  e.g.,	  if	  the	  woman	  is	  having	  difficulties	  to	  conceive,	  or	   for	  other	  emotional	  reasons).	   In	  addition,	   the	  risk	   of	   spontaneous	   miscarriage	   is	   much	   higher	   in	   the	   first	   trimester	   when	   NIPT	   is	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performed,	   and	   of	   course	   it	   should	   not	   be	   discounted	   that	   the	   implementation	   of	   NIPT	  would	  be	  less	  burdensome	  on	  the	  national	  health	  system.	  In	   Italy	   invasive	   cytogenetic	   tests	   are	   offered	   free	   of	   charge	   through	   the	   SSN	   to	   all	  women	  older	  than	  35	  years	  of	  age;	  women	  with	  previous	  children	  affected	  by	  chromosomal	  abnormalities;	   in	   case	   of	   one	   parent	   with	   structural	   chromosomal	   rearrangement	   not	  associated	   with	   any	   phenotypic	   effect	   and;	   in	   case	   of	   anatomical	   anomalies	   detected	   at	  scanning;	  or	   in	   case	  of	  positive	   result	  of	   combined	   test.	  Compared	   to	   traditional	   invasive	  cytogenetic	   tests,	   such	   as	   CVS	   or	   amniocentesis,	   NIPT	   is	   able	   to	   detect	   92	   %	   of	   foetal	  chromosomal	  anomalies	  which	  are	  detectable	  prenatally,	  and	  96	  %	  of	  foetal	  chromosomal	  anomalies	  detected	  at	  birth	  (the	  discrepancy	  between	  the	  two	  being	  due	  to	  the	  fact	  some	  pregnancies	  with	  malformations	  do	  not	  result	  in	  the	  birth	  of	  a	  viable	  child),	  reaching	  a	  level	  of	   detection	   rate	   very	   similar	   to	   the	   one	   of	   traditional	   foetal	   karyotyping	   (the	  characterization	   of	   an	   individual’s	   chromosomal	   complement)	   	   obtained	   with	   invasive	  cytogenetic	   testing	   	   of	   96.9%1.	   In	   addition,	   compared	   to	   invasive	   cytogenetic	   tests,	  NIPT	  testing	  would	  not	  only	  offer	  the	  advantages	  of	  being	  non-­‐invasive	  and	  being	  offered	  earlier	  on	  in	  the	  pregnancy,	  but	  would	  also	  avoid	  some	  of	  the	  critical	  care	  and	  emergency	  (urgent)	  situations	   that	   are	   frequent	   in	   the	   traditional	   invasive	   diagnosis.	   These	   critical	   care	  instances	  are	  not	  only	  distressful	  for	  the	  woman,	  but	  pose	  also	  a	  cost	  to	  the	  national	  health	  system.	  It	  is	  important	  to	  note	  at	  this	  point	  that,	  even	  in	  the	  case	  in	  which	  NIPT	  were	  offered	  to	  all	  pregnant	  women,	  it	  would	  not	  substitute	  completely	  the	  combined	  test,	  as	  the	  latter	  as	  mentioned	  above	  also	  offers	  information	  on	  the	  risk	  of	  cardiac	  malformations,	  which	  would	  not	   be	   captured	   by	   the	   NIPT.	   For	   these	   reasons	   it	   should	   be	   recommended	   that	   blood	  sampling	   for	   NIPT	   should	   be	   always	   associated	   with	   a	   first	   trimester	   scan	   with	   nuchal	  translucency	  evaluation.  It	  is	  also	  important	  to	  note	  that	  the	  NIPT	  results	  could	  be	  affected	  by	  other	  factors	  that	  do	  not	  affect	  the	  combined	  test,	  resulting	  possibly	  in	  false	  positive,	  or	  in	  incidental	  findings	  related	  to	  the	  mother.	  These	  are:	  a) Maternal	   constitutional	   mosaicisms:	   as	   NIPT	   is	   performed	   on	   maternal	   and	   foetal	   DNA,	  there	  could	  be	  an	  anomaly	  in	  the	  chromosomal	  karyotype	  of	  the	  mother,	  for	  example	  due	  to	  an	  anomalous	  cell	   line	  of	  the	  mother	  non	  necessarily	   linked	  to	  any	  phenotypical	  anomaly	  [11]	  b) 	  Maternal	   chromosomal	   anomalies	   of	   iatrogenic	   origin	   (non-­‐constitutional):	   similarly	   the	  result	   of	   the	   test	   can	   be	   compromised	   by	   the	   presence	   in	   the	   blood	   of	   mutated	   DNA	  fragments	   from	   the	  mother	   caused	  by	  pharmacological,	   physical,	   or	   viral	   agents	   that	   can	  damage	  DNA	  
                                                
1 http://www.salute.gov.it/imgs/C_17_pubblicazioni_2381_allegato.pdf	  (accessed	  April	  4th,	  2016) 
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c) 	  Vanishing	   twin:	   in	   case	   of	   a	   twin	   pregnancy	   in	   which	   one	   of	   the	   two	   twins	   was	  spontaneously	  interrupted	  this	  could	  result	  in	  fragments	  from	  placental	  DNA	  of	  an	  aborted	  foetus	  in	  the	  first	  few	  weeks	  [12]	  Both	  one	  and	  two	  can	  not	  only	  compromise	  the	  result	  of	  the	  test	  (potentially	  leading	  to	  a	  false	  positive	  result)	  but	  also	  raise	  ethical	  issues,	  as	  they	  could	  involve	  uncovering	  hidden	  anomalies	   in	   a	   parent(s)	   and	   their	   families,	   including	   potentially	   an	   abnormal	   cell	   line	  which	  can	  indicate	  a	  non-­‐diagnosed	  cancer,	  [13]	  or	  even	  lead	  indirectly	  to	  paternity	  testing.	  	   In	  the	  UK,	  the	  standard	  Down	  Syndrome	  Screening	  (DSS)	  offered	  through	  the	  NHS	  is	  also	   a	   combined	   test	   at	   10-­‐14	   weeks.	   It	   involves	   a	   maternal	   serum	  marker	   test	   and	   an	  ultrasound	  imaging	  scan.2	  Similarly	  to	  Italy	  and	  the	  UK,	   in	  China,	  all	  women	  are	  currently	  offered	  Down	  Syndrome	   Screening	   (DSS)	   through	   foetal	   ultrasound	   scan,	   combined	  with	  maternal	  serum	  biomarkers.	  However,	  DSS	  has	  a	  false	  positive	  rate	  of	  3	  -­‐	  5%	  and	  only	  80-­‐90%	  detection	  rate	  [14].	  Therefore,	  an	  invasive	  test	  in	  the	  form	  of	  amniocentesis	  or	  CVS	  is	  still	  required	  to	  confirm	  the	  positive	  test.	  However,	  there	  is	  about	  0.5-­‐1%	  miscarriage	  risk	  related	  to	  these	  invasive	  methods	  [15].	   	   	  If	  the	  positive	  result	  is	  confirmed	  at	  the	  invasive	  test,	   the	   woman	   will	   be	   advised	   to	   go	   through	   a	   post	   diagnosis	   counselling	   process	   to	  decide	  whether	   to	   continue	   her	   pregnancy	   or	   not.	   However,	   as	  we	   note	   below,	   in	  many	  countries,	  including	  the	  ones	  we	  are	  analysing,	  doctors	  and	  healthcare	  professionals	  do	  not	  seem	   to	   be	   adequately	   prepared	   to	   offer	   genetic	   counselling	   for	   NIPT,	   including	   for	   the	  possible	  incidental	  findings	  mentioned	  above.	  	  	  	  
3.	  The	  ‘how’	  is	  used	  depends	  on	  where	  is	  used:	  market	  and	  regulation	  of	  NIPT	  	   While	   the	   technology	   underlying	  NIPT	   is	   relatively	   simple	   and	  well-­‐established,	   the	  uses	  of	  the	  test	  differ	  greatly	  in	  the	  countries	  we	  analysed.	  This	  is	  not	  surprising	  as	  how	  a	  technology	  is	  used	  is	  dependent	  on	  the	  cultural,	  social	  and	  political	  context	  of	  each	  country.	  In	   Italy	   NIPT	   is	   not	   reimbursed	   by	   the	   SSN	   (Sistema	   Sanitario	   Nazionale,	   Italian	  national	  health	  system	  and	  equivalent	  of	  NHS),	  but	  is	  offered	  privately	  with	  a	  median	  cost	  of	  €	  571	  (compared	  to	  a	  median	  price	  for	  the	  combined	  test	  of	  €	  104	  and	  median	  price	  for	  invasive	  cytogenetic	  test	  of	  €	  935).3	  As	  noted	  above,	  several	  regional	  and	  national	  working	  groups	  are	  currently	  evaluating	  how	  NIPT	  could	  be	  included	  within	  the	  SSN	  However,	  until	  clear	  guidelines	  are	  formulated,	  there	  is	  a	  tangible	  risk	  that	  NIPT	  can	  be	  offered	  privately	  by	  centres	   that	  are	  not	  competent	   in	  performing	  ultrasound	  scanning,	  prenatal	  diagnosis	  and	  genetic	  counselling	  pre	  and	  post-­‐NIPT.	  
                                                2	  http://www.nhs.uk/conditions/pregnancy-­‐and-­‐baby/pages/screening-­‐amniocentesis-­‐downs-­‐syndrome.aspx	  (accessed	  April	  4th,	  2016)	  3	  http://www.salute.gov.it/imgs/C_17_pubblicazioni_2381_allegato.pdf	  (accessed	  April	  4th,	  2016)	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Similarly	  to	  Italy	  and	  in	  some	  ways	  to	  Brazil,	  NIPT	  is	  also	  flourishing	  in	  the	  UK	  in	  the	  private	   sector,	  where	   it	   is	   offered	   for	   a	   price	   about	   £	   400-­‐	   £	   700,	  with	   results	   available	  within	  two	  weeks.	  For	  these	  private	  clinics,	  ISO	  15189	  and	  CE	  marking	  certification	  are	  the	  compulsory	   conditions	   for	   providing	   the	  NIPT	   service4.	   However,	   the	   implementation	   of	  NIPT	  into	  the	  national	  health	  system	  is	  in	  sight	  for	  2017/2018,	  as	  explained	  at	  the	  end	  of	  this	  section.	  In	  China	  from	  2011	  to	  201,	  NIPT	  prompted	  the	  launch	  of	  many	  companies	  that	  were	  offering	  NIPT	  testing	  privately	  at	  a	  commercial	  price	  of	  about	  2000-­‐3000	  RMB	  (about	  £200	  -­‐	  £	  300)	  in	  China.	  In	  February	  2014,	  after	  the	  Chinese	  commercial	  market	  had	  been	  offering	  NIPT	  for	  more	  than	  three	  years,	  the	  China	  Food	  and	  Drug	  Administration	  (CFDA)	  and	  the	  National	   Health	   and	   Family	   Planning	   Commission	   (NHFPC)	   announced	   that	   all	   genetic	  testing	   including	  NIPT	  was	   suspended	  until	  new	  regulation	  was	   implemented.5.	   In	  China,	  CFDA	  is	  responsible	  for	  the	  supervision	  and	  administration	  of	  medical	  devices	  and	  reagents	  under	  the	  direct	  supervision	  state	  council,	  while	  NHFPC	  has	  the	  responsibility	  to	  formulate	  and	   carry	   out	   administrative	   measures	   for	   medical	   institutions	   and	   medical	   services	  industry.	  (http://en.nhfpc.gov.cn/2014-­‐05/07/content_17491484.htm).	  Several	  reasons	  led	  to	  the	  suspension	  of	  NIPT	  in	  China	  in	  February	  2014.	  	  The	  first	  one	  was	   that	   the	   expected	   high	   benefits	   of	   NIPT	   had	   already	   prompted	   the	   launch	   of	   many	  companies	   but,	  without	   any	   regulation	   in	   place,	   CFDA	   and	  NHFPC	   concluded	   that	   it	  was	  impossible	   to	   guarantee	   that	   these	   companies	   had	   the	   capacity	   to	   offer	   clinical	   testing	  including	  NIPT.	  In	  other	  words,	  the	  commercial	  market	  for	  genetic	  testing	  was	  perceived	  to	  be	  chaotic	  with	  no	  guarantee	  that	  the	  companies	  could	  deliver	  what	  they	  promised.	  In	  a	  the	  course	   of	   a	   few	  months	   in	   2014	   CFDA	  worked	   to	   strengthen	   the	   supervision	   of	   genetic	  testing	   and	   produced	   the	   regulations	   for	   Supervision	   and	   Administration	   of	   Medical	  Devices	  (state	  council	  order	  No.	  650),	  Medical	  Device	  Registration	  Administration	  Method	  (CFDA	  order	  No.	  4),	  and	   in	  vitro	  diagnostic	   reagents	  Registration	  Administration	  Method	  (CFDA	  order	  No.	  5).	  Medical	  Devices	  and	  In-­‐vitro	  Diagnosis	  have	  been	  divided	  into	  class	  I,	  II	  and	   III,	   taking	   into	   account	   their	   inherent	   risks	   from	   low	   to	   high.	   According	   to	   The	  Classification	   for	   Medical	   Devices	   (2002),	   all	   reagents	   and	   devices	   for	   gene	   testing	   are	  under	  Class	   III.	  NIPT	  belongs	   to	  Class	   III	  which	  needs	   registration	  examination	  by	  CFDA.	  Between	  March	  and	  May,	  2014,	  BGI	  (where	  one	  of	  the	  authors,	  Zeng,	  works)	  had	  completed	  10,598	   samples	   in	   20	   hospitals	   and	   clinical	   centres	   in	   China	   for	   clinical	   validity.	   	   BGI	  submitted	   the	   registration	   of	   the	   detection	   kit	   for	   NIPT	   (T21,	   T18,	   T13)	   (Combinatorial	  Probe-­‐anchor	   Ligation	   Sequencing	  Method/	   Semiconductor	   Sequencing	  Method)	   and	   the	  sequencing	  machines	  BGISEQ-­‐1000	  and	  BGISEQ-­‐100	   for	  NIPT	   to	  CFDA	   in	   June,	   2014.	  On	  June	  30th,	  2014,	  CFDA	  approved	  BGISEQ-­‐1000	  and	  BGISEQ-­‐100	   for	  medical	  applications,	  
                                                4	  ISO	  15189:	  http://www.iso.org/iso/home/store/catalogue_ics/catalogue_detail_ics.htm?csnumber=56115;	  CE	  marking:	  	  http://ec.europa.eu/growth/single-­‐market/ce-­‐marking/index_en.htm	  (accessed	  April	  4th,	  2016) 
5 http://www.sda.gov.cn/WS01/CL0845/96853.html	  (accessed	  April	  4th,	  2016) 
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hence	  BGI	  received	  the	  first	  certificate	  for	  NIPT	  in	  China.	  	  In	  the	  meantime,	  BGI	  and	  China	  National	  Institute	  for	  Food	  and	  Drug	  control	  had	  built	  up	  the	  national	  reference	  panel:	  the	  DNA	   reference	   sequence	   control	   materials	   for	   sequencing	   performance	   evaluation6.	   In	  January	  2015,	  NHFPC	  had	  approved	  108	  medical	  institutions	  as	  NIPT	  clinical	  trial	  sites.	  On	  July	  2nd,	  2015,	  NHFPC	  announced	  the	  “Notice	  of	  NHFPC	  on	  the	  cancellation	  of	  Class	   III	  of	  medical	   technique	   clinical	   application	   access	   approval,”	   which	   means	   the	   medical	  institutions	  can	  now	  offer	  NIPT	  without	  NHFPC’s	  approval.7.	  This	  does	  not	  mean	  that	  NIPT	  has	  been	  declassed	  to	  class	  II,	  but	  only	  that	  NHFPC	  has	  changed	  the	  regulation	  rule	  for	  class	  III	  and	  the	  registration	  of	  the	  medical	  devices	  and	  reagents	  for	  NIPT	  in	  CFDA	  remains	  the	  only	  condition	   for	  a	  medical	   institution	  or	  a	  commercial	  company	  to	  provide	  NIPT	  to	   the	  public.	  In	  December	  2015,	  NIPT	  was	  officially	   included	   in	   the	  handbook	  of	  prenatal	   care	  of	  Shenzhen.8	  This	   was	   the	   official	   recognition	   that	   NIPT	   had	   been	   adopted	   in	   the	   public	  clinical	   system	   in	   Shenzhen,	   where	   NIPT	   is	   recommended	   at	   14-­‐20	   weeks.	   Pregnant	  women	  in	  Shenzhen	  pay	  880	  RMB	  (about	  £	  90)	  for	  NIPT,	  with	  the	  remaining	  cost	  of	  the	  test	  (more	   than	   half	   of	   the	   price)	   being	   subsided	   by	   the	   Shenzhen	   government.	   In	   some	  provinces	   in	  China,	  such	  as	  Xichuan	  province	  and	  Zhejing	  province,	   the	  Development	  and	  Reform	  Commission	  has	  set	  a	  price	  of	  the	  NIPT	  which	  is	  proportional	  to	  what	  people	  earn.	  	  In	  China,	   there	   is	  no	  systematic	   training	   in	  genetic	  counselling:	  Genetic	  counsellor	   is	  not	   a	   professional	   career	   and	   there	   is	   no	   official	   authentication.	   Since	   NIPT	   is	   still	   an	  advanced	   and	   innovative	   technique,	   the	   majority	   of	   doctors	   still	   lack	   the	   appropriate	  knowledge	  on	  how	  to	  use	  it	  and	  how	  to	  offer	  appropriate	  pre-­‐	  and	  post-­‐counselling.	  This	  is	  obviously	  a	  problem	  that	  needs	  to	  be	  addressed.	  The	  BGI9	  (where	  one	  of	  the	  authors,	  Zeng,	  works)	   and	  NHFPC	   Talent	   Exchange	   Service	   Center	   have	   been	   pioneers	   in	   this	   sense	   by	  holding	  a	  series	  of	  genetics	  counselling	  training	  courses	  for	  doctors	  in	  China	  in	  2015.	  10	  The	   situation	   in	   Brazil	   is	   again	   different.	   Abortion	   is	   illegal	   in	   Brazil	   for	   any	   foetal	  indication,	  with	   the	   sole	   exceptions	   of	   anencephaly	   and	   rape	   [16].	   As	   a	   consequence	   the	  Brazilian	  national	  health	  system	  SUS	  (Sistema	  Unico	  de	  Saude)	  did	  not	  introduce	  prenatal	  diagnosis	  or	  screening	  tests	  to	  pregnant	  women.	  	  Illegal,	  however,	  does	  not	  mean	  rare:	  one	  in	   every	   five	   Brazilian	   women	   was	   reported	   to	   have	   an	   abortion	   [17].	   As	   the	   Brazilian	  physician	   and	   author	   of	   popular	   books	   about	  medicine	   Drauzio	   Varella	   explained	   in	   the	  context	   of	   the	   debate	   on	   risk	   of	   induction	   of	   foetal	   malformation	   by	   the	   Zika	   virus,	   an	  abortion	  for	  foetal	  indication	  is	  freely	  accessible	  in	  Brazil	  -­‐	  for	  those	  who	  can	  afford	  it	  [18].	  It	  means,	  however,	   that	  only	  affluent	  women	  have	  access	   to	  safe	  abortions	  [16].	   In	  many	  
                                                6	  http://www.sda.gov.cn/WS01/CL0051/102239.html	  (accessed	  April	  4th,	  2016)	  7http://www.nhfpc.gov.cn/yzygj/s3585/201507/c529dd6bb8084e09883ae417256b3c49.shtml	  (accessed	  April	  4th,	  2016) 
8 Shenzhen	  is	  the	  first	  province	  in	  China	  to	  have	  adopted	  NIPT	  into	  the	  public	  clinical	  system. 
9 http://www.genomics.cn/en/index	  (accessed	  April	  4th,	  2016) 
10 http://www.genomics.cn/news/show_news?nid=104519	  (accessed	  April	  4th,	  2016) 
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areas,	   among	   them	   gynaecology	   and	   obstetrics,	   middle	   and	   upper	   class	   women	   use	  exclusively	   private	   sector	   services.	   Brazilian	   physicians,	   especially	   those	   who	   work	   in	  upper-­‐end	  private	  clinics,	  tend	  to	  prescribe	  numerous	  complex	  diagnostic	  tests,	  partly	  as	  a	  status	   symbol:	   such	   tests	   stand	   for	   cutting-­‐edge,	   high	   quality	  medicine.	   For	   this	   reason,	  private	   Brazilian	   hospitals	   often	   purchase	   expensive	   diagnostic	   equipment	   such	   as	  sophisticated	   ultrasound	   and	  magnetic	   resonance	   imagery	  machines.	   It	   is	   in	   this	   private	  sector	   that	   NIPT	   has	   flourished	   in	   the	   last	   three	   years.	   Pregnant	   women	   treated	   in	   the	  private	   sector	   undergo	  usually	   some	   form	  of	   screening	   for	  Down	   syndrome	   risk:	   usually	  (similarly	   to	  what	  happens	   in	   Italy,	  UK	  and	  China)	  a	   combination	  of	  a	   serum	   test	  and	  an	  ultrasound	  examination	  at	  11-­‐12	  weeks	  of	  pregnancy.	  If	  these	  tests	  uncover	  a	  high	  risk	  of	  Down	   syndrome	   or	   another	   inborn	   anomaly,	   the	   woman	   usually	   undergoes	   an	  amniocentesis,	   and	   if	   the	   result	   is	   positive,	   she	   can	   chose	   to	   have	   an	   illegal	   -­‐	   but	   safe	   -­‐abortion.	   The	   low	   number	   of	   children	   with	   inborn	   defects	   born	   in	   private	   hospital	   and	  clinics	   indirectly	  attests	   to	   the	  popularity	  of	  abortions	   for	   foetal	  anomalies	   in	   the	  private	  sector	  [19].	  	  The	  use	  of	  NIPT	  in	  Brazil	  has	  entered	  this	  economy	  of	  diagnostic	  testing	  through	  the	  US.	  Indeed,	  US	  producers	  of	  NIPT	  became	  very	  interested	  in	  the	  sizable	  Brazilian	  market	  in	  2013,	  when	  the	  US	  firms	  Ariosa	  and	  Natera	  signed	  agreements	  with	  Brazilian	  laboratories	  and	   now	   offer	   NIPT,	   together	   with	   other	   blood	   tests,	   such	   as	   a	   serum	   test	   for	   Down	  syndrome	  risk	  as	  part	  of	  the	  clinics	   ‘package	  deal’	  of	  prenatal	  care.11	  The	  test	   is	  relatively	  inexpensive;	  in	  2015	  its	  price	  was	  around	  300-­‐400	  reals,	  that	  is,	  approximately	  $80-­‐	  $100.	  	  In	   early	   2013,	   the	   Brazilian	   press	   presented	   the	   new	   test	   to	   their	   readers,	   with	  headlines	  such	  as,	  'Looking	  for	  the	  perfect	  DNA',	  or	  'Blood	  test	  which	  detects	  Down	  syndrome	  
arrives	   to	   Brazil.'	   [20,21].	   The	   latter	   article	   explained	   that	   NIPT	   will	   help	   families	   to	   be	  better	   prepared	   to	   an	   arrival	   of	   a	   Down	   syndrome	   child,	   and	   was	   illustrated	   with	   a	  photograph	  of	  a	  smiling	  middle	  class	  couple	  with	  a	  cute	  Down	  syndrome	  girl	   [20].	  Down	  syndrome	   is	   systematically	   presented	   in	  Brazilian	  media	   as	   a	   difference,	   not	   a	   disability,	  with	  a	  strong	  focus	  on	  the	  blessings	  of	  having	  an	  ‘angel-­‐child’	  [22-­‐24].	  The	  prescription	  of	  NIPT	  has	  become	  dissociated	  from	  a	  calculus	  of	  individual	  risk	  and	  became	   a	   test	   that	   aims	   to	   reassure	   every	   pregnant	   woman	   that	   her	   baby	   is	   'all	   right'.	  Laboratories	  that	  offer	  NIPT	  in	  Brazil	  took	  into	  account	  this	  specificity	  of	  the	  local	  market.	  
                                                11	  'Ariosa	  Diagnostics	  and	  Fleury	  Group	  Announce	  Offering	  of	  the	  Highly	  Accurate	  Harmony™	  Prenatal	  Test	  in	  Brazil	  to	  Assess	  Risk	  for	  Chromosome	  Conditions	  in	  Singleton	  and	  Twin	  Pregnancies',	  Ariosa	  Diagnostic	  News,	  Sept.	  12,	  2013	  http://www.americanownews.com/story/23412770/ariosa-­‐diagnostics-­‐and-­‐fleury-­‐group-­‐announce-­‐offering-­‐of-­‐the-­‐highly-­‐accurate-­‐harmony-­‐prenatal-­‐test-­‐in-­‐brazil-­‐to-­‐assess-­‐risk-­‐for-­‐chromosome-­‐conditions;	  DASA	   Group	   to	   Provide	   Natera’s	   Panorama™	   Non-­‐Invasive	   Prenatal	   Test	   for	   Detection	   of	   Chromosomal	  Abnormalities,	  Such	  as	  Down	  Syndrome,	  from	  the	  Ninth	  Week	  of	  Gestation,	  Business	  Wire,	  August	  8,	  2013,	  	  http://www.businesswire.com/news/home/20130808005340/en/DASA-­‐Group-­‐Provide-­‐Natera%E2%80%99s-­‐Panorama%E2%84%A2-­‐Non-­‐Invasive-­‐Prenatal	  (accessed	  April	  4th,	  2016)	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Gene	   Laboratorio's	   advertisement	   of	   the	   Panorama	   test	   (produced	   by	   Natera),	   entitled	  'Healthy	   baby,	   serene	   pregnancy'	   explains	   that	   there	   are	   two	   versions	   of	   the	   test,	   a	  'conventional'	  test	  that	  detects	  trisomies	  21,	  13	  and	  18,	  and	  sex	  chromosomes	  anomalies,	  and	  an	  'amplified'	  test,	  which	  includes	  also	  testing	  for	  five	  major	  chromosomal	  deletions.12	  The	  advertisement	  adds	  that	  while	  Down	  syndrome	  is	  more	  frequent	  in	  older	  women,	  the	  risk	   of	   microdeletions	   does	   not	   depend	   on	   age:	   women	   under	   thirty	   are	   therefore	   at	   a	  higher	  risk	  to	  have	  a	  child	  with	  a	  microdeletion	  than	  with	  Down	  syndrome.13	  The	  implicit	  message	   is	   that	   pregnant	   woman	   of	   any	   age	   should	   invest	   in	   NIPT	   to	   have	   a	   ‘serene	  pregnancy’.	  Private	   	   laboratories	  such	  as	  Centro	  Paolista	   	  de	  Diagnostica,	  Pesquisa	  e	  Tratamento,	  or	  Laboratorio	  Gene	  de	  Belo	  Horizonte,	  included	  in	  their	  publicity	  information	  about	  NIPT	  for	  Down	  syndrome.	   In	   fall	   2013	   specialists	   from	  private	   gynaecological	   clinics	  were	  not	  persuaded	   that	   the	   test	  would	   be	   popular	   in	   Brazil.	   A	   possible	   obstacle	   for	   its	   diffusion,	  they	  thought,	  would	  be	  its	  price:	  approximately	  2,000	  reals	  for	  testing	  for	  trisomies	  21,	  18	  and	  13	  and	  the	   foetal	  sex,	  non	  reimbursed	  by	  health	   insurance	  companies.	  The	  price	  of	  a	  serum	   test	   for	   Down	   syndrome	   risk	   (usually	   PAPP-­‐A	   test)	   was	   200-­‐300	   reals,	   and	   of	   a	  testing	  for	  foetal	  sex,	  300-­‐400	  reals.	  Women	  could	  therefore	  obtain	  comparable	  (although	  less	  reliable)	  information	  at	  a	  much	  lower	  cost.	  	  One	   year	   later,	   NIPT	   for	   Down	   syndrome	   became	   part	   of	   the	   prenatal	   testing	  landscape	   in	   the	  Brazilian	  private	  health	   sector.	  This	   trend	  was	   amplified	   in	  2015.	   Some	  professionals	   explained	   that	   they	  were	   surprised	   by	   the	   rapidity	   of	   adoption	   of	   the	   new	  technology.	   Contrary	   to	   their	   earlier	   suppositions,	   the	   price	   of	   the	   test	   did	   not	   seem	   to	  discourage	   affluent	   women	   who	   wanted	   to	   be	   sure	   their	   child	   would	   not	   be	   impaired.	  Professionals	   interviewed	   by	   one	   of	   the	   authors	   (Löwy)	   (not	   a	   representative	   sample)	  thought	  also	  that	  the	  uptake	  of	  this	  test	  was	  not	  limited	  to	  women	  over	  35	  who	  wished	  to	  avoid	   amniocentesis,	   and	   was	   popular	   also	   among	   young	   women	   with	   very	   low	   risk	   of	  giving	   birth	   to	   a	   Down	   syndrome	   child.	   Not	   infrequently	   women	   arrived	   at	   their	   first	  diagnostic	   ultrasound	   examination,	   conducted	   at	   11-­‐12	   weeks	   of	   pregnancy,	   with	   their	  NIPT	  results.	  One	   of	   the	   particularities	   of	   Brazilian	   prenatal	   testing	   in	   the	   past	   few	   years	   is	   an	  increasing	  popularity	  of	  ccfDNA	  based	  tests	  exactly	  for	  early	  detection	  of	  foetal	  sex	  for	  the	  middle	   and	   upper	   class	   women.	   This	   test	   became	   available	   in	   numerous	   industrialized	  countries	   in	   the	   first	   years	   of	   the	   21	   century	   and	   was	   independently	   elaborated	   by	  Brazilian	   researchers.[25]	   The	   test	   is	   relatively	   simple	   since	   one	   does	   not	   need	   next	  
                                                12	  These	  deletions	  are	  DiGeorge	  syndrome	  (22q11deletion,	  frequency	  of	  1	  in	  2000	  live	  births),	  1p36	  deletion	  syndrome	   (frequency	   1	   in	   5000)	   ,	   cri	   du	   chat	   syndrome	   (5p	   deletion,	   frequency	   1:20,000),	   Angleman	  syndrome	  (maternal	  15q11-­‐13	  del,	  	  frequency	  1	  in	  12000),	  and	  	  Prader	  Willy	  syndrome	  (paternal	  15q11-­‐13	  del,	  	  frequency	  in	  20,000)	  . 13	  http://www.laboratoriogene.com.br/exames/nipt-­‐teste-­‐pre-­‐natal-­‐nao-­‐invasivo-­‐em-­‐sangue-­‐materno/	  (accessed	  April	  4th,	  2016))	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generation	  sequencing	  (NGS)	  but	  it	  is	  only	  looking	  for	  something	  absent	  in	  maternal	  serum,	  namely	  markers	   on	   the	   Y	   chromosomes.	   There	   is	   no	   patent	  war	   on	   this,	   and	   the	   test	   is	  cheap	  (in	  2015	  	  its	  price	  was	  around	  300-­‐400	  reals,	  that	  is,	  approximately	  $80-­‐	  100).	  This	  test	   has	   been	   included	   from	   about	   2010-­‐11	   as	   part	   of	   the	   package	   of	   care	   in	   private	  maternity	  clinics.	  The	  increasing	  popularity	  of	  this	  test	  for	  sex-­‐determination	  in	  Brazil	  can	  be	  explained	  at	  least	  in	  part	  by	  considering	  that	  in	  Brazil	  knowing	  the	  future	  child’s	  sex	  and	  naming	  her/	  him	  is	  a	  key	  step	  in	  integration	  of	  the	  future	  child	  into	  the	  family.	  Lilian	  Krakowsky	  Chazan	  described	   the	   importance	   role	   of	   learning	   the	   foetal	   sex	   in	   their	   inclusion	   in	   the	   family	  narrative	   [26].	   Another	   explanation	   given	   by	   some	  professionals	   –	   but	  which	  may	   be	   an	  'urban	   legend'	  and	  needs	   to	  be	   taken	  with	  a	  pinch	  of	  salt	   -­‐	   is	   that	  women	  want	   	   to	  know	  early	  on	  the	  sex	  of	  their	  baby	  to	  start	  shopping	  for	  this	  baby	  abroad,	  especially	  in	  Florida.	  It	  would	  very	  interesting	  to	  analyse	  (beyond	  the	  scope	  of	  this	  paper)	  the	  sociological	  aspects	  of	   cross-­‐contamination	   between	   US	   social	   rituals	   of	   preparations	   to	   pregnancy	   such	   as	  ‘baby-­‐shower’	   and	   how	   they	   are	   translated	   into	   a	   Brazilian	   context,	   and	  what	   role	   NIPT	  testing	  plays	  in	  such	  rituals.	  The	   difference	   between	   China	   and	   Brazil	   in	   terms	   of	   uses	   of	   prenatal	   tests	   for	   sex-­‐determination	  is	  striking:	  while	  in	  China	  it	   is	  strictly	  prohibited	  to	  use	  NIPT	  to	  determine	  the	  sex	  of	  the	  foetus,	  in	  Brazil	  cffDNA	  test	  has	  acquired	  an	  increasing	  popularity.	  One	  of	  the	  authors	   is	  based	  at	  BGI,	  one	  of	   the	  world-­‐largest	  genomics	   institutes,	   in	  Shenzhen,	  China.	  Here,	   although	   clinicians	   have	   been	   offering	   NIPT	   to	   detect	   foetal	   chromosomal	  aneuploidies	  since	  2011	  (with	  an	  interruption	  in	  2014	  as	  explained	  above)	  [27],	  NIPT	  for	  sex	  determination	   is	   strictly	  prohibited	   	   according	   to	   the	  population	  and	   family	  planning	  law	  of	  the	  People's	  Republic	  of	  China	  with	  the	  only	  exception	  of	  parents	  who	  are	  carriers	  of	  X-­‐linked	   inheritable	   diseases	   (Article	   35:	   Use	   of	   ultrasonography	   or	   other	   techniques	   to	  identify	  foetal	  sex	  for	  non-­‐medical	  purposes	  is	  strictly	  prohibited.	  Sex-­‐selective	  pregnancy	  termination	  for	  non-­‐medical	  purposes	  is	  strictly	  prohibited.).	  This	  prohibition	  is	  linked	  to	  the	  fear	  of	  selective	  termination	  of	  female	  foetuses,	  a	  fear	  that	  is	  based	  in	  the	  appalling	  data	  about	   the	   gender	   ratio	   in	   China	   in	   the	   last	   thirty	   years.	   China	   lacks	   the	   intense	   cultural	  stigma	   toward	   abortion	   that	   other	   countries	   have	   [28].	   In	   addition,	   to	   control	   the	  population	   in	  China,	   the	  one-­‐child	  policy	  was	   introduced	  between	  1978	  and	  1980.	  While	  the	  birth	   rate	  has	  dropped	  dramatically	   in	   the	   last	   thirty	   years,	   the	   gender	   ratio	   at	   birth	  increased	  as	  a	  consequence	  of	  the	  policy	  and	  cultural	  preference	  for	  male	  children.	  	  Given	  current	  trends,	  it	  has	  been	  estimated	  that	  by	  2020,	  there	  will	  be	  approximately	  30	  million	  more	   adult	   men	   than	   adult	   women.	   The	   one-­‐child	   policy	   has	   been	   recently	   suspended	  (October	  2015)	  mostly	  on	  grounds	  of	  this	  gender	  imbalance	  The	  National	   Institute	   for	  Health	  Research	   (NIHR)	   funded	  RAPID	   (Reliable	  Accurate	  Prenatal	  non-­‐Invasive	  Diagnosis),	  a	  five-­‐year	  UK	  national	  programme	  running	  from	  1	  Jan,	  2009	  to	  30	  Sept,	  2015,	  and	  aimed	  at	  evaluating	  early	  NIPD/NIPT	  based	  on	  cffDNA	  and	  RNA	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in	   maternal	   plasma	   in	   order	   to	   improve	   the	   quality	   of	   National	   Health	   Service	   (NHS)	  prenatal	   diagnostic	   services.	   In	   this	   study	   all	   women	   undergoing	   DSS	   at	   the	   eight	  participating	  units	  and	  who	  have	  a	  risk	  of	  >1:1,000	  were	  offered	  NIPT.	  RAPID	  has	  already	  provided	  two	  positive	  evaluation	  reports	  on	  NIPT	  [29,	  30].	  On	  January	  18th,	  2016,	  the	  UK	  National	  Screening	  Committee	  reported	  evidence	  based	  on	  the	  RAPID	  project	  that	  NIPT	  is	  highly	  accurate	  for	  detection	  of	  foetal	  chromosomal	  aneuploidies	  including	  the	  detection	  of	  trisomy	  21,	  trisomy	  18,	  and	  trisomy	  13,	  and	  recommended	  it	  for	  implementation	  through	  the	  NHS	   to	  all	  women.	   	  The	  UK	  Government	  now	  needs	   to	  approve	   the	   recommendation	  before	  it	  is	  implemented	  by	  the	  NHS.	  If	  the	  UK	  Parliament	  approves	  the	  National	  Screening	  Committee	   recommendation	   (and	   it	   is	   expected	   that	   it	  will),	   in	   the	   near	   future	   (2017	  or	  2018)	  NIPT	  could	  be	  offered	  to	  all	  women	  in	  the	  UK	  in	  substitution	  of	  serum	  test.	  The	  news	  of	  the	  recommendation	  by	  the	  UK	  National	  Screening	  Committee	  to	  the	  for	  implementation	  through	   the	   NHS	   in	   substitution	   of	   invasive	   screening	   has	   been	   met	   with	   some	   vocal	  criticisms	  by	  parents	  of	  Down	  syndrome	  children	  and	  other	  disability	  rights	  scholars	  and	  activists	  in	  the	  UK.	  	  
5.	  Ethical	  issues:	  narrative	  imaginaries	  of	  gender	  and	  disabilities	  	   Disability	   rights	   scholars	   and	   bioethicists	   have	   pointed	   out	   the	   potential	   dangers	   of	  increased	   selective	   termination	   of	   children	   with	   Down	   syndrome	   resulting	   from	   the	  implementation	  of	  NIPT.	  In	  particular	  some	  scholars	  have	  raised	  the	  issues	  that	  the	  offer	  of	  NIPT	  would	   be	   “irresistible”	   and	  would	   create	   pressure	   on	  women	   to	   take	   the	   test	   and	  terminate	   the	   pregnancy	   in	   case	   of	   a	   positive	   result.	   [31,	   32].	   Another	   concern	   that	   has	  been	  raised	  by	  bioethicists	   in	   the	  UK	  regarding	   the	   implementation	  of	  NIPT	   is	   that,	   since	  the	   test	   requires	   only	   a	   very	   simple	  blood	   sample,	   	   it	   could	   lead	   to	   the	   	   “normalisation”,	  “routinisation”	  and	  subsequent	  “trivialisation”	  of	   the	  screening	  practice	  [37],	  which	  could	  lead	   to	   selective	   terminations	   for	   similarly	   “trivial”	   reasons.	  However,	   as	   noted	   by	   Löwy	  [33],	  similar	  earlier	   ‘alarmist	  predictions’	  that	  the	  liberalization	  of	  abortion	  would	  lead	  to	  the	   frequent	   termination	  of	  pregnancy	   for	   ‘trivial	   reasons’,	   (196),	  never	  materialised.	  We	  do	  not	  think	  that	  the	  rate	  of	  therapeutic	  abortions	  will	   increase	  significantly	  compared	  to	  the	  pre-­‐NIPT	  era.	  The	  decision	  to	  have	  an	  abortion	  is	  not	  one	  that	  a	  woman	  will	  ever	  take	  lightly.	   Rather,	   we	   think	   that	   the	   main	   effect	   of	   the	   implementation	   of	   NIPT	   will	   be	   a	  significant	   reduction	   in	   the	   number	   of	   useless	   CVS	   and	   amniocentesis.	   In	   this	   sense,	   the	  implementation	  of	  NIPT	  will	   lead	  to	  a	  modulation,	  and	  not	  to	  a	  revolution,	  of	  the	  existing	  landscape	  of	  prenatal	  testing.	  This	  will	  be	  the	  case	  at	  least	  in	  countries	  such	  as	  UK,	  China	  or	  Italy	   (while	   that	   is	   not	   the	   case	   yet	   in	   Brazil,	   mostly	   because	   abortion	   remains	   illegal)	  where	   all	   women	   already	   undergo	   some	   sort	   of	   combined	   ‘serum	   test’	   and	   ultrasound	  scanning	   for	   nuchal	   translucency	   as	   a	   screening	   for	   Down	   Syndrome	   and	   other	  aneuploidies	  (we	  note	  this	  is	  not	  the	  case,	  for	  example,	  in	  the	  US).	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  As	  pointed	  out	  by	  one	  of	   the	  authors	   (Löwy)	  elsewhere	   [38],	  while	   technologies	  are	  initially	  shaped	  by	  the	  values	  and	  preferences	  of	  people	  who	  develop	  them”	  they	  can	  later	  “be	  modified	  by	  their	  users”.	  (p.	  202)	  For	  example,	   	  amniocentesis	  was	  first	  introduced	  in	  the	  1950s	  to	  look	  at	  blood	  type	  of	  the	  foetus	  and	  save	  the	  foetus	  in	  case	  of	  maternal-­‐foetal	  Rhesus	  factor	  incompatibility,	  not	  for	  prenatal	  screening	  [34].	  Something	  similar,	  as	  shown	  in	  this	  paper,	  is	  already	  happening	  in	  Brazil,	  where	  NIPT	  is	  becoming	  the	  ‘status	  symbol’	  of	  those	  who	  can	  afford	  an	  extra	  package	  for	  their	  children,	  to	  demonstrate	  how	  wanted	  their	  child	  is,	  and	  how	  welcomed	  to	  the	  family	  it	  is.	  An	  upper	  class	  woman	  in	  Brazil	  can	  indeed	  see	  NIPT	  as	  a	  good,	  not	  a	   ‘frivolous’	   investment	   for	   ‘trivial	  reasons’.	  Services	  provided	  by	  the	  high-­‐end	  maternity	  clinics	  are	  usually	  not	  reimbursed	  by	  Brazilian	  health	   insurances.	  Women	  who	  chose	  such	  clinics	  because	  of	  their	  reputation	  of	  excellence	  are	  already	  ready	  to	  pay	   important	  sums	  of	  money	  from	  their	  pocket	   for	  quality	  prenatal	  care.	  The	  price	  of	  NIPT	  (in	  2016)	  was	  not	  very	  high	  when	  compared	  to	  their	  other	  health-­‐related	  expenses.	  In	  a	  sub-­‐culture	  that	  puts	  to	  the	  fore	  the	  consumerist	  aspect	  of	  health	  care	  and	  of	  maternity,	  purchase	   of	   	   a	   non-­‐invasive	   prenatal	   tests	   may	   be	   seen	   as	   a	   less	   frivolous	   version	   of	  purchase	  of	  a	  luxurious	  baby	  pram.	  In	  Brazil,	  NIPT	  has	  become	  smoothly	  integrated	  into	  a	  high	  tech	  supervision	  of	  pregnancy	  accessible	  to	  affluent	  women,	  which	  includes	  testing	  for	  foetal	  anomalies	  and	  (illegal)	  abortions	  for	  such	  anomalies.	  Australian	  philosopher	  and	  author	  of	  Futures	  of	  Reproduction	  (2011)	  Catherine	  Mills	  has	   written	   about	   the	   power	   of	   imaging	   technologies	   in	   bestowing	   moral	   status	   of	   the	  foetus	   or	   “performing	   personhood”	   [34-­‐36]	   with	   ambiguous	   results	   depending	   on	   the	  context	   and	   lived	   experience	   of	   pregnancy:	   it	   makes	   a	   difference	   whether	   the	   imaging	  technology	  is	  used	  as	  in	  some	  US	  states	  to	  discourage	  women	  from	  selectively	  terminating	  a	   pregnancy,	   or	   if	   imaging	   is	   sought	   by	  women	  and	   family	   as	   a	   visual	   narrative	   that	   can	  anticipate	  the	  unborn	  person	  and	  prepare	  its	  acceptance	  into	  the	  world.[36]	  As	  described	  above,	  our	  data	  on	  the	  use	  of	  NIPT	  in	  Brazil	  show	  that,	  in	  a	  similar	  way	  to	  when	  it	  is	  used	  for	  sex	  determination,	  NIPT	  can	  be	  used	  to	  detect	   trisomy	  21	  and	  prepare	   the	  couple	   for	  the	  arrival	  of	  the	  child	  affected	  by	  Down	  syndrome.	  In	  this	  sense,	  NIPT	  testing	  pairs	  with	  imaging	   technologies	   to	   create	   and	   anticipate	   the	   expectation	   of	   the	   future	   child,	   which	  through	  the	  technology	  acquires	  the	  status	  of	  future	  child	  and	  member	  of	  the	  family.	  This	  is	  valid	  both	  to	  detect	  Down	  syndrome	  children	  and	  for	  sex	  determination.	  As	  the	  narrative	  of	  the	  Down	  syndrome	  child	  in	  Brazil	   is	  very	  pervasive,	  the	  trait	  is	  not	  necessarily	  seen	  as	  a	  disability	   but	   as	   a	   difference	   to	   be	  welcomed.	   The	   cognitive	   health	   impairments	   are	   not	  necessarily	   perceived	   as	   something	   to	   ‘get	   rid	   of’	   as	   they	   are	   seen	   to	   be	   linked	   with	  desirable	   qualities	   of	   Down	   syndrome	   identity,	   such	   as	   compassion,	   generosity	   and	  openness.	   It	   is	   therefore	   possible	   to	   speculate	   that	  NIPT	  would	   not	   necessarily	   trigger	   a	  selective	  termination	  in	  case	  of	  a	  positive	  result,	  although	  we	  do	  not	  have	  data	  to	  support	  this	  hypothesis.	  Hence	  we	  recommend	  that	  empirical	  data	  on	  the	  uptake	  of	  NIPT	  and	  the	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decisions	   taken	   by	   women	   as	   a	   result	   of	   a	   positive	   test	   are	   collected	   following	   the	  implementation	  of	  NIPT	  through	  NHS	  in	  UK,	  Italy	  or	  in	  specific	  provinces	  in	  China	  (as	  we	  mentioned	  above,	  it	  is	  unlikely	  that	  NIPT	  will	  be	  offered	  through	  SUS	  in	  Brazil).	  	  	  	   We	  should	  also	  like	  to	  comment	  on	  the	  striking	  difference	  between	  China	  and	  Brazil	  in	  terms	  of	  uses	  of	  NIPT	  for	  sex-­‐determination:	  while	  NIPT	  gained	   increasing	  popularity	   for	  sex	  determination	  in	  Brazil	  with	  the	  upper-­‐middle	  class,	  in	  China	  it	  is	  strictly	  prohibited	  to	  use	  NIPT	  to	  determine	  the	  sex	  of	  the	  foetus.	  This	  is	  due	  to	  the	  fact	  that	  while	  in	  China	  there	  is	  a	  strong	  evidence	  of	  preference	  for	  boys	  over	  girls	  and	  evidence	  of	  selective-­‐termination	  which	  led	  to	  a	  disparity	  in	  sex	  ratios	  over	  the	  past	  thirty	  years,	  in	  Brazil	  all	  the	  interrogated	  health	  professionals	  agreed	  that	  they	  do	  not	  have	  strong	  preference	  for	  boys,	  and	  that	  it	  is	  highly	   unlikely	   that	   a	   woman	   will	   abort	   a	   female	   foetus.	   In	   China,	   as	   Down	   Syndrome	  Screening	   already	   exists	   in	   the	   public	   health	   system	   and	   is	   linked	   to	   the	   possibility	   of	  selective	   termination;	   it	  does	  not	   seem	  plausible	   to	   speculate	   that	   the	   implementation	  of	  NIPT	  on	  a	  wide	  scale	  would	   increase	   the	  rate	  of	  abortion.	   In	  China,	   the	  main	  reasons	   for	  abortion	   are	   likely	   to	   remain	   linked	   to	   sexual	   discrimination,	   even	   with	   the	   current	  suspension	  of	   the	  one-­‐child	  policy	  (families	  who	  have	  one	  female	  child	  may	  try	  to	  have	  a	  second	  male	  child	  to	  continue	  their	  heritage).	  	  Other	  issues	  that	  seem	  to	  us	  to	  deserve	  ethical	  attention	  pertain	  to	  how	  to	  deal	  with	  possible	  incidental	  findings	  resulting	  from	  a	  maternal	  chromosomal	  mosaicisms	  due	  to	  an	  anomalous	  (possibly	  cancerous)	  cellular	  line,	  and	  other	  hidden	  abnormalities	  in	  one	  of	  the	  parents,	  including	  genetic	  diseases	  with	  late	  expressions	  in	  life	  [11].	  	  The	  counselling	  step	  following	  a	  positive	  result	  will	  be	  of	  the	  utmost	  importance.	  As	  highlighted	  above,	  in	  China	  doctors	  are	  not	  trained	  in	  genetic	  counselling.	  In	  Italy	  the	  genetic	  counselling	  is	  included	  in	  the	  NIPT	   fee,	   i.e.	   if	   the	  NIPT	  results	  show	  high	  risk,	   the	  private	  company	  will	  offer	   to	   the	  couple	   genetic	   counselling	  without	   charging	  any	  additional	   cost.	   In	  Brazil	   some	  high-­‐end	  clinics	   provide	   genetic	   counselling	   for	   women	   who	   test	   'positive’	   but	   this	   is	   at	   the	  discretion	  of	  the	  woman's	  doctor	  -­‐	  and	  of	  course	  the	  woman	  has	  to	  pay	  for	  this	  service.	  But	  as	  we	  have	  noted	  above,	  as	  long	  as	  NIPT	  is	  offered	  by	  private	  companies	  and	  not	  through	  the	  national	  health	  system,	  there	  is	  a	  tangible	  risk	  that	  it	  can	  be	  offered	  by	  centres	  that	  are	  not	   competent	   in	   performing	   ultrasound	   scanning,	   prenatal	   diagnosis	   and	   genetic	  counselling	  pre	  and	  post-­‐NIPT.	  	  
6.	  Conclusions	  	   Contrary	   to	  what	  others	  have	  argued,	   this	  paper	  has	  shown	  that	   in	   the	   immediate	  future	   we	   think	   that	   NIPT	   will	   be	   limited	   to	   ‘modulating’,	   not	   drastically	   changing	   or	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revolutionising,	   the	   use	   of	   existing	   diagnostic	   approaches,	   at	   least	   in	   the	   countries	   we	  analysed	  (the	  US	  situation	  is	  different).	  	  However,	  we	  note	  how	  in	  the	  more	  distant	  (but	  not	  too	  far	  ahead!)	  future	  the	  impact	  of	  the	  NIPT	  technology	  will	  be	  different,	  as	  researches	  such	  as	  Whole	  Genome	  Sequencing	  (WGS)	  analysis	  based	  on	  NIPT	  are	  ongoing	  [39]	  and	  it	  is	  plausible	  to	  speculate	  that	  in	  the	  future	  WGS	  will	   be	   offered	   in	   conjunction	   to	   NIPT.	   Future	   evolutions	   of	   NIPT	   combined	  with	  whole	  genome	  sequencing	  (WGS)	   	  will	  make	  the	  foetus	  even	  more	  accessible	  to	  that	  ‘medical	   gaze’	   that	   has	   been	   already	   drastically	   changed	   the	   meaning	   of	   pregnancy	   for	  millions	   of	  women	   since	   the	   introduction	   of	   ultrasound	   scanning	  with	   the	   emergence	   of	  foetal	  images.	  [34,	  36]	  NIPT	  testing	  needs	  to	  be	  positioned	  within	  this	  trajectory	  of	  prenatal	  diagnosis	   that,	   as	   argued	   by	   Löwy,	   	   “displays	   the	   role	   of	   conflicting	   values	   (and	   often	  incommensurable	  moral	   economies)	   in	   the	   emergence	   of	   new	   technologies,	   and	   in	   their	  transformation	   into	   routine	   medical	   procedures”	   [38,	   187].	   The	   two	   ‘often	  incommensurable	   moral	   economies’	   are	   women’s	   autonomy	   and	   individual-­‐centred	  medicine,	   as	  emphasised	   in	  gynaecologists	  and	  midwives/obstetricians’	  public	  discourse;	  and	   considerations	   about	   the	   cost/efficacy	   of	   long-­‐term	   care	   for	   people	   with	   Down	  Syndrome	   or	   other	   chromosomal-­‐related	   disabilities	   as	   emphasized	   in	   public	   health	  discourses.	  These	   two	   contrasting	   narratives	   are	   also	   at	   play	   (more	   or	   less	   covertly)	   in	   the	  discourses	  around	  NIPT.	  It	  seems	  to	  us	  that	  bioethics	  scholarship	  has	  failed	  to	  engage	  thus	  far	   with	   the	   ethical	   issues	   that	   arise	   at	   the	   nexus	   of	   these	   conflicting	   values	   and	  moral	  economies,	   as	   it	   has	   focused	   only	   on	   the	   former	   framing,	   and	   discussion	   of	   possible	  conflicts	   between	   women’s	   rights	   to	   self-­‐determination	   and	   autonomy	   and	   children’s	  future	  rights;	  or	  on	  the	  latter	  framing	  and	  the	  disability	  rights	  critiques	  to	  the	  screening.	  It	  is	   important	   that	   bioethics	   scholarship	   engages	   proactively	   with	   the	   ethical	   issues	   that	  arise	   at	   the	  nexus	   of	   these	   conflicting	   values	   and	  moral	   economies.	   Such	   an	   engagement	  would	  lead	  shift	  the	  focus	  of	  the	  ethical	  analysis	  from	  questions	  such	  as	  ““In	  what	  ways	  is	  it	  ethically	   acceptable	   to	   use	   NIPT?”	   to:	   “In	   what	   ways	   will	   the	   implementation	   of	   NIPT	  through	  the	  NHS	  change	  the	  ways	  in	  which	  women	  think	  about	  their	  pregnancy?”,	  and	  “In	  what	   ways	   will	   women	   be	   held	   responsible	   for	   the	   types	   of	   pregnancies	   they	   decide	   to	  carry?”	   among	   others,	   and	   to	   seriously	   engage	   with	   socio-­‐ethical	   issues	   created	   by	  upstream,	  top-­‐down	  decisions	  on	  implementation	  of	  a	  technology.	  NIPT	  coupled	  with	  WGS	  will	  lead	  to	  a	  completely	  new	  level	  of	  ‘supervision’,	   ‘management’	  and	  ‘scrutiny’	  of	  human	  foetuses	  and	  pregnant	  women,	  that	  we	  have	  a	  responsibility	  to	  start	  discussing	  now,	  taking	  into	  account	  first	  and	  foremost	  the	  voices	  of	  the	  pregnant	  women.	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